Lexicon Pharmaceuticals (NASDAQ:LXRX) is moving forward with Phase III trials for its non-opioid pain medication, pilavapadin, despite a topline miss earlier this year. Analysts at…
September 05, 2025
Amneal Pharmaceuticals Secures FDA Approval for Risperidone Extended-Release Injectable Suspension
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) has announced a significant milestone with the U.S. Food and Drug Administration (FDA) granting approval for its risperidone extended-release injectable…
July 24, 2025
Candel Therapeutics Gains EMA Orphan Designation for CAN-2409, Advancing Pancreatic Cancer Treatment
Pancreatic cancer, one of the deadliest cancer types, has long lacked effective therapeutic options, leaving many patients with modest hope for extended survival. However, a…
February 26, 2025
Shares of Madrigal Pharmaceuticals Surge as Fresh Biennial Data Highlights Possible Advantages of Rezdiffra in Treating Compensated Fatty Liver Cirrhosis
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) revealed the two-year outcomes from the Phase 3 MAESTRO-NAFLD-1 analysis of Rezdiffra (resmetirom) in patients with compensated MASH cirrhosis on Wednesday….
Dogwood Therapeutics, Inc. (Nasdaq: DWTX), a biopharmaceutical firm in its development stage, centered on bringing forth pioneering class, non-opioid treatments such as the Nav 1.7…
December 19, 2024
Psyence Biomed Advances Phase 2b Trial, Inks Exclusive Licensing Deal, Shares Surge 67%
Psyence Biomed (Nasdaq: PBM) continues to gain momentum, activating two Australian trial sites for its Phase 2b psilocybin study in Palliative Care and preparing to…
October 17, 2024
Poseida Therapeutics Announces New CAR-T Development Candidate Under Roche Collaboration
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell therapy company, has announced the nomination of a new allogeneic CAR-T therapy candidate as part of its…
ANEW Medical, Inc. (NASDAQ: WENA) a biopharmaceutical company specializing in the advancement of novel disease-modifying therapies for neurological and age-related disorders, experienced a 147% surge…
BioAdaptives, Inc. (OTC: BDPT) is targeting a slice of the $22B global menstrual health market with the launch of PluriPain®-PMS, an advanced, all natural anti-inflammatory…